{"nctId":"NCT01098318","briefTitle":"Rhodiola Rosea Therapy of Major Depressive Disorder","startDateStruct":{"date":"2010-06"},"conditions":["Depression"],"count":58,"armGroups":[{"label":"Rhodiola rosea","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Herbal extract"]},{"label":"Sertraline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sertraline"]},{"label":"Sugar pill","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Lactose monohydrate"]}],"interventions":[{"name":"Herbal extract","otherNames":["Golden root"]},{"name":"Sertraline","otherNames":["Zoloft"]},{"name":"Lactose monohydrate","otherNames":["Milk powder"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women (all races and ethnicity) ≥ 18 years old\n* DSM IV Axis I diagnosis of mild to moderate Major Depressive Disorder\n* Baseline CGI/S rating of 3 ('mild') or 4 ('moderate')\n* Baseline Hamilton Depression Rating score ≥ 10\n* Not receiving other antidepressant therapy\n* Able to provide signed informed consent\n\nExclusion Criteria:\n\n* Patients \\< 18 years old\n* Current primary DSM IV Axis I diagnosis other than Major Depressive Disorder\n* CGI/S rating of 5 ('marked'), 6 ('severe') or 7 ('very severe')\n* Actively suicidal or requiring hospitalization\n* Uncontrolled medical condition\n* Pregnant or nursing women\n* Women of child-bearing potential not using a medically acceptable form of contraception\n* Concurrent use of herbal remedies or mineral supplements \\[Note: Use of mineral supplements prescribed for medical purposes (e.g., osteoporosis) will not be excluded\\]\n* Current use of chemotherapy or other medication (e.g., interferon) known to produce fatigue or mood changes\n* Known sensitivity to R. rosea or sertraline\n* History of non-response to sertraline in the current depressive episode","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12.","description":"Hamilton Depression Rating Scale (HAM-D) is a validated, clinician-rated instrument for ascertaining the severity of MDD symptoms. The 28-item Hamilton Depression Rating Scale was used to determine the primary outcome of 17-item HAM-D score. The HAM-D will serves as the primary outcome measure. HAM-D17 score ranges from 0 to 68. Higher score indicates more depressed symptom.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":"5.4"},{"groupId":"OG001","value":"8.3","spread":"4.5"},{"groupId":"OG002","value":"8.9","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"6"},{"groupId":"OG001","value":"7.8","spread":"4.3"},{"groupId":"OG002","value":"8.5","spread":"6.7"}]}]}]},{"type":"SECONDARY","title":"The Clinical Global Impression (CGI) Severity and Change","description":"A clinician-rated measure of global symptom severity (CGI/S) and symptom change (CGI/C) of MDD. Severity was rated as \"Not ill\"; \"Borderline ill\"; \"Mild\"; \"Moderate\"; \"Moderately severe\"; \"Severe\" and \"Extremely severe\". Global change was rates as \"Very much improved\"; \"Much improved\"; \"Minimally improved\"; \"Unchanged\";\"Minimally worse\";\"Much worse\" and \"Very much worse\". Here in severity, we reported the N(%) of subjects who were not ill or borderline ill. In change, we reported N(%) of subjects who were \"Very much improved\" or \"Much imp\\[roved\".Subjects started the study with mild to moderate MDD (moderate or above rating in the CGI-S). At WK12, the #/% of subjects in each treatment group who were not ill at WK12 (CGI-S) and who had much improved or very much improved at WK12 (CGI-C) was reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Depressive Symptoms as Measured by the Beck Depression Inventory","description":"All enrolled subjects were analyzed. Mean change in Beck Depression Inventory (BDI) total scores were reported. BDI is a self-reported outcome measuring the severity of depression. A negative # means a reduction in BDI score at the end of treatment compared to baseline which represents an improvement in depression symptoms. BDI total score ranges from 0-63. BDI score of 1-16 represents low level of depression;17-30 represents moderate level of depression; \\>=31 represents significant level of depression. A reduction in the BDI score represents improvement in the depression symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"10.0"},{"groupId":"OG001","value":"-13.7","spread":"5.1"},{"groupId":"OG002","value":"-7.5","spread":"12.2"}]}]}]},{"type":"SECONDARY","title":"Change in Sexual Function","description":"This is a patient completed rating of sexual function and satisfaction. It is used to assess current sexual health and changes in sexual health over time measured by the overall sexual satisfaction score. The reported score is the overall degree of sexual satisfaction attained. The score ranges from 0 to 100. Higher score indicates more sexual satisfaction.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"25.5","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Suicide Ideation as Determined by the Columbia Suicide Form","description":"Descriptive analysis of number of subjects in each treatment group who had suicidal ideation at baseline and WK12.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Side Effects","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Nausea","Nervousness","Sexual dysfunction","Dizziness"]}}}